References
- Hawkey PM. Quinolones in sweat and quinolone resistance commentary). Lancet 1997; 349: 148–9.
- Wiedemann B, Heisig P. Mechanisms of quinolone resistance. Infection 1994; 22: (Suppl 2): S73–9.
- Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995; 49 (Suppl 2): 36–42.
- Davis R, Bryson H. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677–700.
- Ball P, Fernald A, Tillotson G. Therapeutic advances of new fluoroquinolones. Exp Opin Invest Drugs 1998; 7: 1–23.
- Tillotson GS, Dorrian I. Longitudinal UK survey of the activity of ciprofloxacin against Gram-negative bacteria since 1987. 1st European Congress of Chemotherapy, Glasgow 1996: Abstract T104.
- Felmingham D, Robbins M, Tesfaslasie Y, Harding I, Shrimpton S, Grüneberg RN. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995–1996 cold season. J Antimicrob Chemother 1998; 41: 411–15.
- Hickey ML, Thornsberry C, Diakun DR, Mani SV, Sahm DF. Activity of ciprofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis: has it changed in the last decade? 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998: Abstract E-20.
- Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 1994; 22: (Suppl 2): S111–21.
- Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 1990; 26 (Suppl F): 165–79.
- MeReC Bulletin Report. Levofloxacin and grepafloxacin – two new quinolone antibiotics. MeReC Bull 1998; 8: 29–32.
- Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. J Antimicrob Chemother 1998; 42: 114–120.
- Haria M, Lamb HM. Trovafloxacin. Drugs 1997; 54: 435–45.
- Wiedemann B, Heisig P. Antibacterial activity of grepafloxacin. J Antimicrob Chemother 1994; 40 (Suppl A): 19–25.
- Paladino J, Rifenburg R, Bhavnani S, Schentag J. Economic and resistance effects of converting from ciprofloxacin to ofloxacin. 20th International Congress of Chemotherapy, Sydney 1997: Abstract 4116.
- Pozdol T, Postelnick M, Peterson L, Reisberg B, Noskin G. Effect of changes in quinolone usage on Pseudomonas aeruginosa (PSAE) susceptibility patterns. 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy, 1993: Abstract 234.
- Michéa-Hamzehpour M, Auckenthaler R, Regamey P, Pechére J-C. Resistance occurring after quinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31: 1803–8.
- Andrews JM, Honeybourne D, Jevons G, Brenwald NP, Cunningham B, Wise R. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 40: 573–7.
- Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health-Syst Pharm 1997; 54: 2569–84.
- Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Agents Chemother 1997; 39 (Suppl B): 1–14.
- Martinez-Freijo P, Flint AC, Schmitz F-J, Verhoef J, Jones ME. Class I integrons in Gram negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. J Antimicrob Chemother 1998; 42: 689-96.